Ian Cawich, MD
Cardiovascular Disease · Little Rock, ARNPI 1427273432
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 32.1% of the total. Reporting peaked in 2022 at $83,945 and has fallen 60.8% since, to $32,900 in 2025. Among cardiovascular disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 806 payments — averaging $364.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$94K
- Avinger Inc.$69K
- Cardiovascular Systems Inc.$50K
- Shockwave Medical, Inc$29K
- Abbott$29K
- Asahi Intecc USA, Inc.$12K
- plus $10K from 27 others
Across 133 payments — averaging $5863.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mercator Medsystems, Inc.$672K
- Abbott$70K
- Boston Scientific$21K
- W. L. Gore & Associates, Inc.$6K
- Cardiovascular Systems Inc.$4K
- Trireme Medical LLC$4K
- plus $3K from 1 others
What the payments were for
- Consulting fees$83,00128%
- Speaking & faculty fees$149,22351%
- Travel & lodging$18,8716%
- Food & beverage$42,46014%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 157 | $94,321 |
| Avinger Inc. | 322 | $68,834 |
| Cardiovascular Systems Inc. | 41 | $50,392 |
| Shockwave Medical, Inc | 55 | $29,288 |
| Abbott | 59 | $28,764 |
| Asahi Intecc USA, Inc. | 18 | $12,411 |
| Mercator Medsystems, Inc. | 2 | $2,819 |
| Penumbra, Inc. | 25 | $1,483 |
| BD | 20 | $1,118 |
| Boston Scientific | 40 | $858 |
| Abiomed | 7 | $517 |
| Cardiva Medical, Inc. | 5 | $470 |
| Philips North America LLC | 4 | $441 |
| Avantec Vascular Corporation | 2 | $270 |
| Terumo Medical Corporation | 10 | $240 |
| Inari Medical, Inc. | 4 | $239 |
| Cook Medical LLC | 2 | $195 |
| W. L. Gore & Associates, Inc. | 3 | $189 |
| Novartis | 5 | $103 |
| Endologix LLC | 2 | $89 |
| Johnson & Johnson | 5 | $86 |
| Pfizer | 5 | $81 |
| Acist Medical Systems, Inc. | 1 | $78 |
| Cordis US CORP. | 2 | $41 |
| Angiodynamics, Inc. | 1 | $39 |
| Medtronic(2 entities) | 2 | $37 |
| Thrombolex, Inc. | 1 | $35 |
| Livanova USA, Inc. | 1 | $33 |
| Reflow Medical Inc | 1 | $27 |
| Stryker | 1 | $24 |
| Teleflex LLC | 1 | $23 |
| GSK | 1 | $19 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANTHERIS$59,459
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$28,174
- Diamondback Peripheral$27,034
- Omnilink Elite vascular stent system$26,000
- Peripheral Orbital Atherectomy System$22,650
- LUTONIX$15,658
- PERIPHERAL VASCULAR$10,000
- Rotarex$8,792
- ULTRASCORE$5,320
- Bullfrog$2,819
- ASAHI PTCA Guide Wire$2,000
- RotarexS 6 F x 135 cm$1,034
- CARDIOMEMS$987
- CROSSER$950
- Crosser iQ$797
- Indigo System$747
- Xience Sierra Coronary Stent System$451
- VENOVO$412
- Impella$406
- Cardiva VASCADE MVP VVCS 6-12F$250
How this compares
$293,580 in reported general payments places this provider in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $224,469 |
| XareltoRivaroxaban | 72 | $54,066 |
| EntrestoSacubitril/Valsartan | 66 | $45,061 |
| BrilintaTicagrelor | 45 | $22,348 |
| FarxigaDapagliflozin Propanediol | 15 | $9,424 |
| ClopidogrelClopidogrel Bisulfate | 946 | $8,719 |
| Metoprolol Succinate | 290 | $3,672 |
| Prasugrel Hcl | 82 | $3,429 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 208 | $2,728 |
| Atorvastatin Calcium | 199 | $2,227 |
| Ezetimibe | 95 | $2,186 |
| Losartan Potassium | 256 | $2,022 |
| Potassium Chloride | 113 | $1,961 |
| Rosuvastatin Calcium | 117 | $1,284 |
| Ranolazine ErRanolazine | 20 | $1,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $224,469308 claims |
| Johnson & JohnsonXarelto | $86 | $54,06672 claims |
| NovartisEntresto | $103 | $45,06166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
- Michael HuberLittle Rock$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.